Reported 3 days ago
Hims & Hers Health, Inc. (NYSE:HIMS) experienced a remarkable 27.29% increase in its stock price over the past week, closing at $51.96, attributed to strong earnings and expectations of upcoming partnerships. The company's net income surged by 346% year-over-year to $49.5 million, with revenues climbing 111% to $586 million. A significant new deal with Novo Nordisk to market its weight loss drug, Wegovy, along with further partnerships expected, has positioned HIMS strongly in the market.
Source: YAHOO